#1 Clinical Trials Search in Europe

Cibotercept

Cibotercept, also known as KER-012, is an innovative drug currently being studied in clinical trials for the treatment of Pulmonary Arterial Hypertension (PAH). This article explores the ongoing research, potential benefits, and important information about the clinical trials investigating this promising medication for PAH patients.

Table of Contents

What is CIBOTERCEPT?

CIBOTERCEPT, also known as KER-012, is a new medication being studied for the treatment of pulmonary arterial hypertension (PAH). It is a type of drug called a recombinant fusion protein, which means it’s a specially designed protein created in a laboratory[1]. CIBOTERCEPT is made up of two main parts:

  1. A part that mimics a receptor in our body called activin receptor type-2B
  2. A part that comes from a human antibody (IgG1)

This unique structure allows CIBOTERCEPT to interact with certain proteins in the body that are involved in PAH[1].

What Medical Condition Does CIBOTERCEPT Treat?

CIBOTERCEPT is being developed to treat pulmonary arterial hypertension (PAH). PAH is a serious condition where the blood pressure in the arteries of the lungs becomes abnormally high. This makes it harder for the heart to pump blood through the lungs, which can lead to shortness of breath, fatigue, and other symptoms[1].

There are different types of PAH that CIBOTERCEPT aims to treat, including:

  • Idiopathic PAH (when the cause is unknown)
  • Hereditary PAH (when it runs in families)
  • PAH associated with certain drugs or toxins
  • PAH related to connective tissue diseases
  • PAH linked to certain heart defects

How Does CIBOTERCEPT Work?

CIBOTERCEPT works by targeting a group of proteins in the body called the TGF-β superfamily. These proteins play a role in the development and progression of PAH. By interacting with these proteins, CIBOTERCEPT aims to improve the function of blood vessels in the lungs and reduce the high blood pressure that characterizes PAH[1].

Current Clinical Trial: The TROPOS Study

CIBOTERCEPT is currently being studied in a clinical trial called the TROPOS study. This is a Phase 2 study, which means it’s designed to test how well the drug works and how safe it is in people with PAH[1].

The main goals of the TROPOS study are:

  1. To see how CIBOTERCEPT affects the blood flow in the lungs (measured by something called pulmonary vascular resistance or PVR)[1].
  2. To check if CIBOTERCEPT improves how far patients can walk in 6 minutes (a test called the 6-minute walk distance or 6MWD)[1].
  3. To make sure CIBOTERCEPT is safe and well-tolerated by patients[1].

Who is Eligible for the TROPOS Study?

The study is looking for adults (18 years or older) with PAH who meet certain criteria. Some key points for eligibility include:

  • Having PAH that falls into specific categories (like idiopathic PAH or PAH associated with certain conditions)[1].
  • Having certain test results that confirm PAH diagnosis[1].
  • Being on stable PAH medication for at least 90 days[1].
  • Being able to walk between 150 and 500 meters in the 6-minute walk test[1].

There are also some conditions that would prevent someone from participating in the study, such as certain heart or lung problems[1].

How is the TROPOS Study Designed?

The TROPOS study is divided into two main parts:

  1. Treatment Period (24 weeks): Participants are randomly assigned to receive either CIBOTERCEPT at different doses (1.5 mg/kg, 3.0 mg/kg, or 4.5 mg/kg) or a placebo. The medication is given as an injection under the skin every 4 weeks[1].
  2. Extension Period (72 weeks): After the initial 24 weeks, all participants continue in the study for another 72 weeks. Those who were on placebo switch to CIBOTERCEPT, while those already on CIBOTERCEPT continue their treatment[1].

Throughout the study, participants continue taking their regular PAH medications in addition to the study drug[1].

Potential Benefits of CIBOTERCEPT

While it’s important to remember that CIBOTERCEPT is still being studied and its benefits are not yet proven, researchers hope it may:

  • Improve blood flow in the lungs, making it easier for the heart to pump blood[1].
  • Increase how far patients can walk, which could mean improved daily function and quality of life[1].
  • Provide a new treatment option for people with PAH, especially those who may not respond well to current treatments[1].

Safety Considerations

As with any new medication, safety is a top priority in the TROPOS study. The researchers are carefully monitoring for any side effects or adverse reactions. Some things to note:

  • The study excludes people with certain health conditions to minimize risks[1].
  • Participants are closely monitored throughout the study with regular check-ups and tests[1].
  • The study is “double-blind,” which means neither the participants nor the doctors know who is receiving CIBOTERCEPT or placebo. This helps ensure unbiased results[1].

It’s important to remember that CIBOTERCEPT is still an experimental drug. While it shows promise, more research is needed to fully understand its effects and safety profile[1].

Aspect Details
Drug Name Cibotercept (KER-012)
Condition Studied Pulmonary Arterial Hypertension (PAH)
Trial Phase Phase 2
Main Objective Evaluate effect on pulmonary hemodynamics
Secondary Objectives Assess exercise capacity, safety, and tolerability
Treatment Duration 96 weeks (24-week Treatment + 72-week Extension)
Administration Subcutaneous injection every 4 weeks
Dose Levels 1.5 mg/kg, 3.0 mg/kg, 4.5 mg/kg
Primary Endpoint Change in pulmonary vascular resistance at Week 24
Key Secondary Endpoint Change in 6-minute walk distance at Week 24

FAQ

  • What is Cibotercept (KER-012)? Cibotercept, also known as KER-012, is a recombinant fusion protein being studied as a potential treatment for Pulmonary Arterial Hypertension (PAH). It targets specific biological pathways involved in PAH progression.
  • What is the main goal of the clinical trial for Cibotercept? The main objective of the trial is to evaluate the effect of KER-012 on pulmonary hemodynamics compared to a placebo in participants who are already on background PAH therapy.
  • Who can participate in the Cibotercept clinical trial? Adult participants (18 years or older) with symptomatic World Health Organization (WHO) Group 1 Pulmonary Hypertension (PAH) who meet specific medical criteria and are on stable PAH background therapy may be eligible to participate.
  • How long does the clinical trial for Cibotercept last? The trial consists of a 24-week Treatment Period followed by a 72-week Extension Period, for a total of 96 weeks (about 22 months) on treatment.
  • How is Cibotercept administered in the clinical trial? Cibotercept is administered as a subcutaneous injection every four weeks (Q4W) at different dose levels (1.5 mg/kg, 3.0 mg/kg, or 4.5 mg/kg) depending on the assigned treatment arm.

Ongoing Clinical Trials on Cibotercept

  • Study on the Safety and Effectiveness of Cibotercept (KER-012) with Other Drugs for Adults with Pulmonary Arterial Hypertension

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    France Germany Poland Portugal Spain

Glossary

  • Pulmonary Arterial Hypertension (PAH): A rare, progressive disorder characterized by high blood pressure in the arteries of the lungs, which can lead to heart failure.
  • Hemodynamics: The study of blood flow in the circulatory system, including factors such as blood pressure and resistance in blood vessels.
  • Pulmonary Vascular Resistance (PVR): A measure of the resistance to blood flow in the pulmonary arteries, which is often elevated in PAH patients.
  • 6-Minute Walk Distance (6MWD): A test that measures the distance a person can walk in 6 minutes, used to assess exercise capacity and disease progression in PAH patients.
  • World Health Organization (WHO) Functional Class: A system used to classify the severity of symptoms in PAH patients, ranging from Class I (minimal symptoms) to Class IV (severe symptoms).
  • Endothelin-Receptor Antagonist (ERA): A type of medication used to treat PAH by blocking the effects of endothelin, a substance that causes blood vessels to narrow.
  • Phosphodiesterase-5 Inhibitor (PDE5-I): A class of drugs used in PAH treatment that work by relaxing blood vessels and increasing blood flow.
  • Soluble Guanylate Cyclase (sGC) Stimulator: A type of medication used in PAH treatment that helps relax and widen blood vessels in the lungs.
  • Prostacyclin Analogue: A class of drugs used in PAH treatment that mimic the effects of prostacyclin, a natural substance that dilates blood vessels.
  • Subcutaneous (SC): A method of drug administration where the medication is injected just under the skin.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-cibotercept-ker-012-with-other-drugs-for-adults-with-pulmonary-arterial-hypertension/